Myelosuppression After Frontline Fludarabine, Cyclophosphamide, and Rituximab in Patients With Chronic Lymphocytic Leukemia: Analysis of Persistent and New-Onset Cytopenia

BACKGROUND: The combination of fludarabine, cyclophosphamide, and rituximab (FCR) has produced improved response rates and a prolonged survival in patients with chronic lymphocytic leukemia (CLL). However, its therapeutic power is counterbalanced by significant hematologic toxicity. Persistent and n...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Strati, Paolo, Wierda, William, Burger, Jan, Ferrajoli, Alessandra, Tam, Constantine, Lerner, Susan, Keating, Michael J., O’Brien, Susan
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4535913/
https://ncbi.nlm.nih.gov/pubmed/23943357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28318
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars